Valuation : Decoy Therapeutics Inc.

Market Cap 17.62L 15.17L 14.27L 13.03L 24.38L 17Cr 24.45L 1.69Cr 65.43L 8.54Cr 66.18L 64.74L 28Cr P/E 2024 *
-
P/E 2025 -0.06x
Enterprise Value -89.47L -76.99L -72.44L -66.17L -1.24Cr -84Cr -1.24Cr -8.56Cr -3.32Cr -43Cr -3.36Cr -3.29Cr -139.63Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.52%
Yield 2024 *
-
Yield 2025 -

Last Transcript : Decoy Therapeutics Inc.

1 week+704.15%
1 month+639.05%
3 months+459.28%
6 months+454.29%
Current year+435.17%
1 week 2.99
Extreme 2.992
26.62
1 month 2.99
Extreme 2.992
26.62
3 years 2.99
Extreme 2.992
206
5 years 2.99
Extreme 2.992
3,975
Change 5-day change 1-year change 3-year change Capi.($)
-3.96%+704.15%+97.71%-87.33% 17.62L
-1.79%-2.27%+43.23%+88.96% 6.8TCr
-2.06%-0.18%+39.67%+86.44% 6.49TCr
-0.31%+6.54%-12.96%+378.92% 2.76TCr
+0.86%+1.65%-7.74%-14.95% 2.61TCr
-3.00%-2.90%+33.13%+12.54% 2.57TCr
-1.46%+0.42%+23.61%-18.61% 2.01TCr
-2.96%-15.21%+216.20%+368.10% 1.72TCr
-1.49%-4.88%-6.60%+531.89% 1.49TCr
-0.20%+8.37%+55.78%+164.98% 1.46TCr
Average -1.38%+0.26%+48.20%+151.09% 3.1TCr
Weighted average by Cap. -1.52%+0.18%+38.37%+137.35%

Financials

2024 2025
Net sales - -
Net income -55.76L -47.98L -45.14L -41.24L -77.14L -53Cr -77.35L -5.33Cr -2.07Cr -27Cr -2.09Cr -2.05Cr -87Cr -1.25Cr -1.08Cr -1.01Cr -92.58L -1.73Cr -118.19Cr -1.74Cr -12Cr -4.65Cr -61Cr -4.7Cr -4.6Cr -195.36Cr
Net Debt -22.13L -19.04L -17.91L -16.36L -30.61L -21Cr -30.7L -2.12Cr -82.14L -11Cr -83.09L -81.28L -35Cr -1.07Cr -92.16L -86.71L -79.21L -1.48Cr -101.12Cr -1.49Cr -10Cr -3.98Cr -52Cr -4.02Cr -3.93Cr -167.14Cr
Logo Decoy Therapeutics Inc.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
-

Annual profits - Rate of surprise